Personal tools
mission statement

Our Mission: To prioritize, design and execute clinical research that will reduce the public health threat of antibacterial resistance

What is antibacterial resistance?

Introduction of antibacterials into the clinic in the 1940s ushered in a new era of medicine and changed the course of history. Many physicians anticipated that infectious disease would be eliminated as a public health problem. Unfortunately, a vast and possibly limitless pool of potential resistance genes naturally occurring in microbial populations has thwarted this goal. Since antibacterials exert a powerful selective pressure, bacteria can easily acquire resistance through mutation or horizontal gene transfer.


What are the goals of the ARLG?

Our goal is to establish an Antibacterial Resistance Leadership Group (ARLG) that will develop, design, implement, and manage a clinical research agenda to increase knowledge of antibacterial resistance. There are several strategies to combat antibacterial resistance >> LEARN MORE >>

What is the ARLG?

The ARLG is facilitated by the Duke Clinical Research Institute (DCRI) and works under the centralized leadership of an executive committee and two Principal Investigators (PIs). One PI, Dr. Vance Fowler, Duke University, focuses primarily on operations and the other, Dr. Henry "Chip" Chambers, UCSF, focuses largely on the scientific agenda.The organizational structure features internationally recognized leaders in the field appointed to Scientific Subcommittees devoted to four priority areas:


Supported by the National Institute Of Allergy And Infectious
Diseases of the National Institutes of Health under Award Number UM1AI104681